Syapse

This year's ASCO meeting underscored what an exciting time this is for advancements in cancer research, and cancer medicine, and the important impact that this work has for patients with cancer. One of the driving themes of this meeting is the rapid evolution of Precision Oncology, with existing targeted therapies moving “up-stream” to early stage disease. This resulting in a direct impact on cure rates, along with an increasing number of biomarkers and associated druggable targets that are rapidly advancing the development of new cancer treatments.  RWD was a continuing topic at ASCO. An ever important tool in advancing therapies is the leveraging of RWD to support patient care, along with supporting regulatory submissions to the FDA. With regard to patient care, RWD can help assess the compliance with rapidly evolving patient care guidelines, showing the adoption rate of newly approved targeted therapies, and the testing rates for their respective companion diagnostics. RWD also allows for post-approval evaluation of safety and efficacy in the broader population, thus helping to address health care disparities, to include assessing the impact of social determinants of health. During this exciting time, we at Syapse continue to be dedicated to our health system and life science partners in lessening the burden of cancer for all populations. 

A huge congratulations to our team for their successful poster presentation at #ASCO2024, on how we can use geospatial techniques to better understand the influence of social determinants of health on stage at diagnosis for breast, bladder, and non-small cell lung cancers. Check out the research here: https://lnkd.in/edPrP7ub

Check out our new research to be presented at #ASCO24! While most researchers are aware that social determinants of health (SDOH) can influence the cancer journey, SDOHs are rarely used in research due to privacy restrictions. We geocoded the data from the Syapse Learning Health Network, and evaluated the influence of five SDOHs on stage at diagnosis in breast, bladder, and non-small cell lung cancers (NSCLC). To learn more about our findings, stop by the poster presentation on Monday, June 3rd from 9-12pm, or visit our booth #15157! For more information on this study, or to schedule a meeting with a member of our team, click the link below: https://lnkd.in/e2DV68Dh

We're thrilled to announce the expansion of our oncology real-world data offerings with the introduction of Syapse Cohorts: Essentials! Syapse Cohorts: Essentials expands upon Syapse’s existing offering of Enriched Cohorts, and is designed to empower cancer researchers and life science companies with unparalleled insights via fit-for-purpose datasets to address key questions across all cancer types. Want to learn more? Meet our team at ASCO, booth #15157, to discuss how our Essentials and Enriched data offerings can elevate your research and outcomes. Read the full press release here: https://lnkd.in/d2aA2WiN #OncologyData #CancerResearch #RealWorldEvidence #RWD #ASCO2024

As the molecular profile of a patient's tumor becomes the primary driver of therapeutic decision making, as opposed to the tumor's organ site of origin, comprehensive genomic testing is taking on increasing importance. Our new publication uses real-world data to demonstrate the survival benefit of comprehensive genetic testing among patients with advanced non-small cell lung cancer. Read the full publication here: https://lnkd.in/eg8mdzC7

Syapse is thrilled to be exhibiting at #ASCO24 in Chicago from May 31st - June 2nd. As your partner for real-world data solutions in oncology, we are excited to showcase how our expertly-curated datasets can revolutionize your research and clinical endeavors. Visit us at booth 15157 to learn about our off-the-shelf and customizable cohorts that can be tailored to meet your specific research needs, as well as our unique collaboration model, Applied Experience, which enables quality improvement programs with our health system partners. Click the link below to schedule a meeting today! https://lnkd.in/e2DV68Dh

At #NCRA24, Syapse Oncology Data Specialists will present how they are shaping the future of data transformation. Their presentations shed light on innovative methodologies to collect and interpret real-world data that enables cancer research and patient care. Congratulations to the team supporting this important work Donna Rose, ODS-C, Jess Martin AS, HT, ODS-C, Kim Lloyd, RHIT, ODS, and Marianna Wicks, MPH, CTR/ODS. #RWD #RWE #OncologyResearch #CancerCare #ODS

Our Syapse team is looking forward to attending #ISPOR2024 from May 5th to 9th! Connect with us at the conference to learn more about how our cohorts can support your research in over 50 different tumor types. Schedule a meeting with us today: https://lnkd.in/eHeQQxC3

Syapse is thrilled to celebrate Oncology Data Specialists during National Cancer Registrars Week! We are proud to stand with #NCRA in acknowledging #NCRW24 and recognizing the incredible dedication and significance of cancer registrars in collecting essential data that shapes cancer research, prevention, and treatment efforts. This year’s theme, A Diverse Workforce Serving a Diverse Population, speaks volumes to the vital role these professionals play in this multifaceted and evolving profession. A heartfelt thank you goes out to our remarkable ODS team and all the ODS-certified professionals within our Learning Health Network. Your passion and commitment make a real difference in the fight against cancer. Thank you for all that you do! #NCRW24 #ODS #CancerRegistrarsWeek

Congratulations to the Merck and Syapse teams for their work in early-stage NSCLC, which was presented at #NCCN 2024 Annual Conference and honored as one of the Top 5 Abstracts of the meeting! Chenan Zhang Kaitlyn Kane #RWE #RWD #NCCN2024